Muscular Dystrophy



Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Vamorolone 0.25 mg/day/day;   Drug: Vamorolone 0.75 mg/day/day;   Drug: Vamorolone 2.0 mg/day/day;   Drug: Vamorolone 6.0 mg/day/day
Sponsors:   ReveraGen BioPharma, Inc.;   University of Pittsburgh;   Cooperative International Neuromuscular Research Group
Enrolling by invitation - verified April 2017


Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Interventions:   Biological: BMS-986089;   Biological: Placebo for BMS-986089
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified May 2017


Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents


Condition:   Duchenne Muscular Dystrophy
Intervention:   Drug: (+)- Epicatechin
Sponsors:   Craig McDonald, MD;   Cardero Therapeutics, Inc.
Recruiting - verified November 2016


An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:   Biological: PF-06252616
Sponsor:   Pfizer
Recruiting - verified May 2017


Analysis of a Virtual Reality Task in Patients With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Interventions:   Device: Acquisition on TouchScreen;   Device: Acquisition on Kinect;   Device: Acquisition on LeapMotion
Sponsor:   University of Sao Paulo
Completed - verified April 2017


An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Vamorolone 0.25 mg/day/day;   Drug: Vamorolone 0.75 mg/day/day;   Drug: Vamorolone 2.0 mg/day/day;   Drug: Vamorolone 6.0 mg/day/day
Sponsors:   ReveraGen BioPharma, Inc.;   University of Pittsburgh;   National Institute of Neurological Disorders and Stroke (NINDS);   Cooperative International Neuromuscular Research Group;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2017


A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Vamorolone 0.25 mg/kg/day;   Drug: Vamorolone 0.75 mg/kg/day;   Drug: Vamorolone 2.0 mg/kg/day;   Drug: Vamorolone 6.0 mg/kg/day
Sponsors:   ReveraGen BioPharma, Inc.;   University of Pittsburgh;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   National Institute of Neurological Disorders and Stroke (NINDS);   Cooperative International Neuromuscular Research Group
Recruiting - verified April 2017


Study of DS-5141b in Patients With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:   Drug: DS-5141b
Sponsors:   Daiichi Sankyo Co., Ltd.;   Orphan Disease Treatment Institute Co., Ltd.
Recruiting - verified August 2016


Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2


Condition:   Duchenne Muscular Dystrophy
Interventions:   Biological: rAAVrh74.MCK.GALGT2;   Other: PLACEBO (Saline)
Sponsor:   Kevin Flanigan
Withdrawn - verified November 2016


The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy


Condition:   Muscular Dystrophy
Interventions:   Drug: Tadalafil 20 MG;   Other: beetroot juice extract
Sponsor:   Cedars-Sinai Medical Center
Recruiting - verified March 2017


Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: SRP-4045;   Drug: Placebo
Sponsor:   Sarepta Therapeutics
Active, not recruiting - verified May 2017


Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:   Biological: rAAVrh74.MCK.micro-Dystrophin
Sponsors:   Jerry R. Mendell;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting - verified November 2016


Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:   Biological: rAAV1.CMV.huFollistin344
Sponsors:   Jerry R. Mendell;   Duchenne Alliance;   Milo Therapeutics
Active, not recruiting - verified March 2017


Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: PRO044 SC 6 mg/kg;   Drug: PRO044 IV 6 mg/kg;   Drug: PRO044 IV 9 mg/kg
Sponsor:   BioMarin Pharmaceutical
Terminated - verified April 2015


A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Interventions:   Biological: PF-06252616;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2017


Stem Cell Therapy in Muscular Dystrophy


Condition:   Muscular Dystrophy
Intervention:   Biological: Stem Cell
Sponsor:   Neurogen Brain and Spine Institute
Recruiting - verified September 2016


Stem Cell Therapy in Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:   Biological: Stem Cell
Sponsor:   Neurogen Brain and Spine Institute
Completed - verified September 2016


Cell Therapy in Limb Girdle Muscular Dystrophy


Condition:   Limb Girdle Muscular Dystrophy
Intervention:   Biological: Stem Cell
Sponsor:   Neurogen Brain and Spine Institute
Completed - verified September 2016


L-citrulline and Metformin in Duchenne's Muscular Dystrophy


Condition:   Duchenne's Muscular Dystrophy (DMD)
Interventions:   Drug: 750 mg metformin and 7.5 g L-citrulline daily p.o.;   Drug: Placebo
Sponsor:   University Hospital, Basel, Switzerland
Completed - verified August 2016


A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy


Condition:   Congenital Muscular Dystrophy
Intervention:   Other: Hyperinsufflation therapy
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Cure CMD;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 2016


Heart Imaging in Children With Muscular Dystrophy


Condition:   Muscular Dystrophy
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Terminated - verified October 11, 2016


Finding the Optimum Regimen for Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Prednisone;   Drug: Prednisone;   Drug: Deflazacort
Sponsors:   University of Rochester;   Newcastle University;   University Medical Center Freiburg;   National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting - verified January 2017


Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Intervention:  
Sponsors:   University of Florida;   University of Pennsylvania;   Oregon Health and Science University;   Children's Hospital of Philadelphia;   Shriners Hospitals for Children;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2017


A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy


Condition:   Muscular Dystrophies
Intervention:   Drug: GSK2402968 6mg/kg/week
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy


Condition:   Duchenne Muscular Dystrophy
Interventions:   Drug: Epigallocatechin-Gallate;   Drug: Placebo
Sponsor:   Charite University, Berlin, Germany
Active, not recruiting - verified April 2017

Refine Your Search Advanced Search